CD19 and systemic lupus erythematosus: In an in vivo study using a humanized mouse model of SLE, it was observed that CD19 CAR-Tregs delayed the onset of B cell lymphopenia, produced immunomodulatory cytokines, showed no toxicity or reprogramming towards Th17 pro-inflammatory cells, and furthermore, in the inflamed organs, restored the normal composition of the local immune site (76).